CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
Multiplex pharmacokinetic profiling +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01684943
NCT01684943N/ACompleted

Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling

Massachusetts General Hospital·interventional·Posted Sep 13, 2012·Updated Dec 12, 2019

In Brief

A clinical study evaluating Multiplex pharmacokinetic profiling and Continuous insulin monitoring for Type 1 Diabetes. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The investigators are doing this research study to compare the pharmacokinetics (PK) (rate of absorption) of insulin lispro (Humalog), insulin aspart (Novolog), and insulin glulisine (Apidra) within individual subjects. Additionally, the investigators will perform a preliminary feasibility evaluation of a minimally invasive continuous insulin monitoring (CIM) device and its use to derive PK parameters in human subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 13, 2012
Enrollment StartJul 1, 2010
Primary CompletionSep 1, 2016
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 13.8 years ago

Interventions

Multiplex pharmacokinetic profilingother

Continuous insulin monitoringother